Skip to Content

Are you based in North America? If yes, switch to our North American website →

BCL6 Breakapart

Applications
haematology
Catalogue Numbers
LPH 035-S (5 tests)
LPH 035 (10 tests)

Probe Specification

  • BCL6, 3q27.3, Red
  • BCL6, 3q27.3, Green

The BCL6 product consists of a 165kb probe, labelled in red, centromeric to the BCL6 gene and a green probe, covering a 170kb region telomeric to the BCL6 gene.

Probe Information

Chromosomal rearrangements involving the BCL6 (B-cell CLL/lymphoma 6) gene at 3q27 are recognised recurrent abnormalities commonly seen in patients with B-cell malignancy1.

BCL6 rearrangements are the most common chromosomal abnormalities seen in diffuse large B-cell lymphoma (DLBCL), occurring in up to 35% of cases2. They are also seen frequently in follicular lymphoma, where they occur in up to 15% of cases3. BCL6 is expressed in normal germinal centre B-cells and follicle helper T-cells. BCL6 translocations alter expression by promoter substitution and cause deregulated expression of normal BCL6 protein1,4.

Approximately 50% of BCL6 translocations will involve one of the three immunoglobulin loci (IGH, IGL or IGK); the remainder of translocations involve one of more than twenty different non-immunoglobulin genes5. Additionally, gains and amplifications of the BCL2 gene have also been reported in cases of B-cell lymphoma6.

The presence of concurrent BCL6 rearrangements with MYC and/or BCL2 rearrangements in patients with ‘dual-hit’ lymphoma has been shown to be associated with aggressive disease7.

I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support.  The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care.  The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa C. Brown, Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine

References

  1. Wagner SD et al., Br J Haematol 2011;152(1):3-12
  2. Lossos I et al., Leukemia 2003;17(7):1390-7
  3. Akasaka T et al., Blood. 2003;102(4):1443-8
  4. Ye BH, et al. EMBO J 1995;14(24):6209-17
  5. Ohno H, J Clin Exp Hematop 2006;46(2):43-53
  6. Karube K, et al., Mod Pathol 2008;21(8):973-8
  7. Aukema SM, et al., Blood. 2011;24;117(8):2319-31
  8. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
  9. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
  10. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.

Microscope Images

BCL6 Breakapart magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.